Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
Friday, February 21, 2025CSL Behring KK today announced that it has received manufacturing and marketing approval from Japans Ministry of Health Labour and Welfare MHLW for ANDEMBRY garadacimab Subcutaneous SC Injection mg Pens
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
Friday, February 21, 2025Roche unveiled today its proprietary breakthrough sequencing by expansion SBX technology establishing a new category of nextgeneration sequencing SBX chemistry combined with an innovative sensor module offers ultrarapid highthroughput sequencing that...
CDMO Live Debuts as BioPharma Manufacturing Sector Approaches $200 Billion
Friday, February 21, 2025CDMO Live has emerged as the definitive industry gathering bringing together Europes leading pharmaceutical outsourcing decisionmakers at Rotterdams World Trade Center this May putting the spotlight on this critical sector
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.
Thursday, February 20, 2025Medigene AG an oncology platform company focused on the research and development of T cell receptor TCRguided therapies for the treatment of cancer announced today that the Company has been issued a patent by the US Patent Office protecting its JOVI...
Qureight core imaging platform deployed within Vicore Phase 2b ASPIRE study of buloxibutid for IPF
Thursday, February 20, 2025Qureight Ltd a Core Imaging Laboratory developing deeplearning image analytics and Vicore Pharma a clinicalstage biopharmaceutical company unlocking the potential of angiotensin II type receptor agonists ATRAGs today announce the implementation of Q...
Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
Wednesday, February 19, 2025Longeveron Inc a clinical stage regenerative medicine biotechnology company developing cellular therapies for lifethreatening and chronic agingrelated conditions today announced that the International Nonproprietary Names INN Expert Committee of the...
Nomination period opens for IHF Awards and i-to-i Innovation Hub 2025
Wednesday, February 19, 2025The International Hospital Federations Awards the premier annual awards programme for hospitals and healthcare organizations worldwide will celebrate years of rewarding excellence in healthcare leadership at the edition
Isomorphic Labs Announces Novartis Collaboration Expansion
Wednesday, February 19, 2025Isomorphic Labs IsoLabs an AIfirst drug design company today announced that it has entered into an agreement to expand its strategic research collaboration with Novartis This fiollows the announcement of IsoLabs research collaboration with Novartis o...
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
Wednesday, February 19, 2025Silo Pharma Inc a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems today announced the filing of a provisional patent application with the US Patent and Trademark Office USPTO for its lead asset SP...
LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7
Tuesday, February 18, 2025LimmaTech Biologics AG a clinicalstage biotech company developing vaccines for the prevention of lifethreatening diseases announced today that the first participants have been vaccinated in a Phase controlled study of its multivalent vaccine candida...
